tiprankstipranks
Trending News
More News >
Arovella Therapeutics Limited (AU:ALA)
ASX:ALA

Arovella Therapeutics Limited (ALA) Stock Statistics & Valuation Metrics

Compare
12 Followers

Total Valuation

Arovella Therapeutics Limited has a market cap or net worth of AU$92.34M. The enterprise value is AU$124.20M.
Market CapAU$92.34M
Enterprise ValueAU$124.20M

Share Statistics

Arovella Therapeutics Limited has 1,183,870,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,183,870,600
Owned by Insiders
Owned by Institutions

Financial Efficiency

Arovella Therapeutics Limited’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)
Return on Assets (ROA)
Return on Invested Capital (ROIC)
Return on Capital Employed (ROCE)
Revenue Per Employee
Profits Per Employee
Employee Count
Asset Turnover
Inventory Turnover

Valuation Ratios

The current PE Ratio of Arovella Therapeutics Limited is ―. Arovella Therapeutics Limited’s PEG ratio is ―.
PE Ratio
PS Ratio76.03
PB Ratio
Price to Fair Value
Price to FCF
Price to Operating Cash Flow
PEG Ratio

Income Statement

In the last 12 months, Arovella Therapeutics Limited had revenue of 17.00K and earned -8.75M in profits. Earnings per share was -0.01.
Revenue17.00K
Gross Profit-25.98K
Operating Income-10.81M
Pretax Income-8.75M
Net Income-8.75M
EBITDA-8.83M
Earnings Per Share (EPS)-0.01

Cash Flow

In the last 12 months, operating cash flow was -8.23M and capital expenditures -146.67K, giving a free cash flow of -8.38M billion.
Operating Cash Flow-8.23M
Free Cash Flow-8.38M
Free Cash Flow per Share>-0.01

Dividends & Yields

Arovella Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.46
52-Week Price Change-25.00%
50-Day Moving Average0.12
200-Day Moving Average0.16
Relative Strength Index (RSI)49.16
Average Volume (3m)2.60M

Important Dates

Arovella Therapeutics Limited upcoming earnings date is Aug 27, 2025, TBA Not Confirmed.
Last Earnings DateFeb 26, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend Date

Financial Position

Arovella Therapeutics Limited as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio
Quick Ratio
Debt to Market Cap
Net Debt to EBITDA
Interest Coverage Ratio

Taxes

In the past 12 months, Arovella Therapeutics Limited has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate

Enterprise Valuation

Arovella Therapeutics Limited EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales
EV to EBITDA
EV to Free Cash Flow
EV to Operating Cash Flow

Balance Sheet

Arovella Therapeutics Limited has AU$12.71M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of -AU$12.71M billion.
Cash & Marketable SecuritiesAU$12.71M
Total DebtAU$0.00
Net Cash-AU$12.71M
Net Cash Per Share-AU$0.01
Tangible Book Value Per Share

Margins

Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin
Operating Margin
Pretax Margin
Net Profit Margin
EBITDA Margin
EBIT Margin

Analyst Forecast

The average price target for Arovella Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast315.11%
EPS Growth Forecast51.16%

Scores

Smart Score1
AI Score39.5
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis